LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 11, 2017--
Corporation (NASDAQ:QTRX), a company with a next generation,
ultra-sensitive digital platform that advances precision health, today
announced the closing of its initial public offering of 4,916,480 shares
of common stock at a public offering price of $15.00 per share,
including 641,280 shares sold pursuant to the full exercise of the
underwriters’ option to purchase additional shares. Quanterix received
$73,747,200 in gross proceeds from the offering, prior to deducting
underwriting discounts and commissions and offering expenses payable by
the company. The shares began trading on The NASDAQ Global Market
on December 7, 2017 under the ticker symbol “QTRX.”
J.P. Morgan Securities LLC, Leerink Partners LLC and Cowen and Company,
LLC acted as joint book-running managers for the offering. BTIG,
LLC and Evercore Group L.L.C. acted as co-managers.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on December 6, 2017.
The offering was made only by means of a prospectus. A copy of the final
prospectus related to the offering has been filed with the Securities
and Exchange Commission and may be obtained from J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: (866) 803-9204; Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor, Boston,
MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at email@example.com;
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by
calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
Quanterix is a company digitizing biomarker
analysis with the goal of advancing the science of precision health. The
company’s digital health solution, Simoa, has the potential to change
the way in which healthcare is provided today by giving researchers the
ability to closely examine the continuum from health to disease.
Quanterix’ technology is designed to enable much earlier disease
detection, better prognoses and enhanced treatment methods to improve
the quality of life and longevity of the population for generations to
come. The technology is currently being used for research applications
in several therapeutic areas, including oncology, neurology, cardiology,
inflammation and infectious disease. The company was established in 2007
and is located in Lexington, Massachusetts.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211005809/en/
Source: Quanterix Corporation
Quanterix PR Contact:
Joe Driscoll, 617-301-9400